Ozone Blood Therapy (MAH): How Major Autohemotherapy Works and What the Research Shows
At a Glance
- Major autohemotherapy (MAH) involves drawing blood, exposing it to an ozone-oxygen mixture, and reinfusing it intravenously.
- Proposed mechanisms center on Nrf2 pathway activation, which upregulates the body’s own antioxidant defenses, and modulation of immune signaling.
- Clinical evidence exists for chronic infections, certain autoimmune conditions, and peripheral vascular disease, though most studies are small and few are double-blinded.
- MAH has a favorable safety profile when performed with proper equipment and trained practitioners, but quality control varies widely between clinics.
Ozone therapy is one of those treatments that generates strong reactions on both sides. Proponents claim it treats everything from chronic Lyme to cancer. Critics dismiss it as quackery. The truth, as with most polarizing therapies, falls somewhere in the middle: there is real science behind ozone’s biological effects, there is clinical evidence for specific applications, and there is also a lot of overreach in how it gets marketed.
This article focuses specifically on major autohemotherapy (MAH), the most common and well-studied form of systemic ozone therapy. We will cover exactly how the procedure works, what is happening at the molecular level, what the clinical research actually shows, and how MAH compares to newer protocols like 10-pass ozone.
What Is Major Autohemotherapy?
Major autohemotherapy is a medical procedure in which a practitioner draws approximately 100 to 250 mL of the patient’s blood into an IV bag or bottle, mixes it with a precise concentration of medical-grade ozone (O3) blended with oxygen, and then reinfuses the ozonated blood back into the patient’s vein. The entire process typically takes 30 to 60 minutes.
The procedure has been used in clinical practice since the 1950s, primarily in Germany, Italy, Cuba, and Russia, where it has a longer regulatory and clinical history than in the United States. In the U.S., ozone therapy exists in a regulatory gray area: it is not FDA-approved as a treatment for any specific condition, but it is legally practiced in many states by licensed physicians under their medical practice authority.
The MAH Procedure Step by Step
- Blood is drawn from a vein into a sterile, ozone-resistant glass bottle or specialized IV bag (standard PVC bags degrade on contact with ozone).
- Medical-grade ozone is generated from pure oxygen using a calibrated ozone generator. The ozone concentration is typically set between 20 and 70 micrograms per milliliter (mcg/mL), depending on the clinical indication.
- The ozone-oxygen mixture is introduced into the blood, which changes color from dark venous red to a brighter cherry red as the blood is oxygenated and ozone reacts with plasma components.
- The treated blood is reinfused intravenously over 15 to 30 minutes.
- Some practitioners add heparin or sodium citrate as an anticoagulant to prevent clotting during the process.
How Ozone Works in the Body: The Proposed Mechanisms
Ozone itself is highly reactive and does not survive long in biological fluids. When ozone contacts blood, it reacts almost immediately with lipids, proteins, and antioxidants in the plasma to produce secondary messengers, primarily lipid oxidation products (LOPs) like 4-hydroxynonenal (4-HNE) and hydrogen peroxide (H2O2). These secondary messengers are what actually produce the biological effects attributed to ozone therapy.
Nrf2 Pathway Activation
The Nrf2 (nuclear factor erythroid 2-related factor 2) pathway is the body’s master regulator of antioxidant defense. Under normal conditions, Nrf2 is kept inactive in the cytoplasm. When cells detect oxidative stress signals like those produced by ozone’s secondary messengers, Nrf2 translocates to the nucleus and activates the transcription of dozens of protective genes, including those encoding glutathione, superoxide dismutase, heme oxygenase-1, and catalase.
This is the central paradox of ozone therapy: a controlled, mild oxidative stress triggers the body’s own antioxidant systems to upregulate. The concept is similar to how exercise (a form of oxidative stress) makes your body stronger over time. Velio Bocci, the Italian physician-scientist who spent decades studying ozone’s biochemistry, called this “oxidative preconditioning.”
A 2016 study published in Mediators of Inflammation confirmed that ozone exposure in human blood samples activated the Nrf2 pathway and increased glutathione levels. Multiple animal studies have shown similar results, with ozone preconditioning protecting against ischemia-reperfusion injury in liver, kidney, and cardiac tissue models.
Immune Modulation
Ozone exposure affects multiple arms of the immune system. When blood is ozonated and reinfused, the treated white blood cells (particularly monocytes and lymphocytes) release cytokines including interferon-gamma, interleukin-2, and tumor necrosis factor-alpha in moderate, controlled amounts. This has led researchers to describe MAH as a form of “autovaccination” that resets immune signaling without the immunosuppression caused by drugs like corticosteroids.
Ozone also appears to shift the immune balance between Th1 and Th2 responses. In conditions where the immune system is overactivated in one direction (as in many autoimmune diseases), ozone may help restore equilibrium. The evidence for this is primarily from in vitro studies and small clinical trials, not large randomized controlled trials.
Improved Oxygen Delivery
Ozone increases levels of 2,3-diphosphoglycerate (2,3-DPG) in red blood cells, which shifts the oxygen-hemoglobin dissociation curve to the right. In plain language, this makes hemoglobin release oxygen more readily to tissues. For patients with poor circulation or chronic hypoxic conditions, this effect could theoretically improve tissue oxygenation. Bocci documented this effect in multiple studies, showing measurable increases in arterial pO2 after MAH treatments.
What the Clinical Research Shows
Chronic Infections
Ozone therapy has the longest clinical track record for chronic and recurrent infections, particularly in countries like Cuba where it has been used extensively in hospital settings. Studies have examined MAH for chronic hepatitis B and C (showing improvements in viral load and liver enzymes in small trials), recurrent herpes simplex, chronic wound infections, and as an adjunct to antibiotics in resistant bacterial infections. A 2019 review in Medical Gas Research summarized the evidence and concluded that ozone showed consistent antibacterial, antiviral, and antifungal properties in vitro, with mixed but generally positive results in clinical settings.
Evidence note: Most clinical studies on ozone therapy for infections are observational or use small sample sizes without blinding. The in vitro evidence for ozone’s antimicrobial properties is strong, but translating that to clinical outcomes is not straightforward. Larger, well-designed trials are needed.
Autoimmune Conditions
The immune-modulating effects of MAH have led clinicians to use it as an adjunct therapy in autoimmune conditions including rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. A 2018 Italian study found that patients with rheumatoid arthritis receiving MAH alongside standard therapy showed greater reductions in inflammatory markers (CRP, ESR) and clinical symptom scores than those receiving standard therapy alone. Case series from integrative medicine clinics report improvements in autoimmune symptoms, but controlled trials remain scarce.
Peripheral Vascular Disease
This is one of the better-studied applications of MAH. Multiple European trials have examined ozone therapy for peripheral arterial disease and diabetic foot ulcers. A 2005 randomized controlled trial published in the European Journal of Pharmacology found that MAH significantly improved walking distance and reduced claudication symptoms in patients with peripheral arterial disease compared to standard care. Studies on diabetic foot ulcers have shown accelerated wound healing and reduced amputation rates when ozone therapy is added to standard wound care protocols.
Chronic Fatigue and Fibromyalgia
Clinical reports from integrative medicine practitioners frequently cite improvements in energy, brain fog, and pain levels in patients with chronic fatigue syndrome and fibromyalgia after MAH protocols. However, these conditions are particularly susceptible to placebo effects, and the published evidence consists mainly of case series and uncontrolled observational studies. Controlled trials are needed before strong claims can be made.
MAH vs. 10-Pass Ozone Therapy
10-pass ozone (also called high-dose ozone therapy or OHT) is a newer, more intensive version of autohemotherapy developed by Dr. Johann Lahodny in Austria. Instead of treating one volume of blood, the 10-pass protocol uses a specialized hyperbaric device to draw blood, ozonate it under pressure, and reinfuse it repeatedly, typically 10 times in a single session. This delivers roughly 10 times the ozone dose of a standard MAH treatment.
| Feature | Standard MAH | 10-Pass Ozone |
|---|---|---|
| Blood volume per session | 100 to 250 mL (single draw) | 200 mL per pass x 10 = ~2,000 mL total exposure |
| Ozone dose | 2,000 to 6,000 mcg total | Up to 70,000 mcg total |
| Session duration | 30 to 60 minutes | 60 to 90 minutes |
| Equipment | Standard ozone generator + glass bottle | Specialized hyperbaric ozone device |
| Cost per session | $150 to $350 | $500 to $1,500 |
| Evidence base | Larger body of published research | Limited; mostly clinical experience reports |
| Availability | Widely available | Fewer clinics offer it |
Proponents of 10-pass therapy argue that the higher ozone dose produces stronger and faster clinical responses, particularly for chronic infections and severe inflammatory conditions. The tradeoff is higher cost, a longer session, and a thinner evidence base. For a full comparison, see our guide on 10-pass ozone therapy.
Safety Profile
When performed correctly with proper equipment, MAH has a remarkably good safety record. A 2019 review of over 50 years of published ozone therapy literature found that serious adverse events are rare, occurring in fewer than 0.001% of treatments. The most commonly reported side effects are mild and transient: fatigue after treatment (likely related to immune activation), mild headache, and occasional bruising at the IV site.
The key word is “properly.” Ozone therapy safety depends heavily on:
- Proper equipment: Ozone must be generated from medical-grade oxygen using a calibrated generator with precise concentration controls. The collection vessel must be ozone-resistant (glass or specialized bags, never standard PVC).
- Correct dosing: Ozone concentration and volume must be within established therapeutic ranges. Too little produces no effect; too much can cause hemolysis (destruction of red blood cells).
- Trained practitioners: The provider should have specific training in ozone therapy protocols, not just general IV therapy experience.
- No direct IV ozone: Ozone gas should never be injected directly into a vein. It must always be mixed with blood or saline first. Direct IV injection of ozone gas has caused fatal air embolisms and is the source of most serious adverse events in the historical literature.
Contraindications: MAH should be avoided in patients with G6PD deficiency (a genetic enzyme disorder that makes red blood cells highly susceptible to oxidative damage), active hyperthyroidism, severe anemia, and during pregnancy. Patients on anticoagulant therapy need dose adjustments during the procedure.
What to Expect From a Treatment Protocol
MAH is rarely a one-and-done treatment. Most clinical protocols involve a series of sessions:
- Acute infections: 3 to 6 sessions, 2 to 3 times per week
- Chronic infections: 10 to 20 sessions, 1 to 3 times per week, sometimes followed by monthly maintenance
- Autoimmune support: 10 to 15 sessions initially, then monthly maintenance
- Vascular conditions: 15 to 20 sessions, 2 to 3 times per week initially
- General wellness/optimization: 1 to 2 sessions per month (though the evidence for wellness use is weak)
Many patients report noticing effects after 3 to 5 sessions, with cumulative benefits building over the course of treatment. Response varies significantly between individuals and conditions.
The Bottom Line
Major autohemotherapy is a medical procedure with a plausible biological mechanism, a reasonable safety profile, and clinical evidence that ranges from modest (chronic fatigue) to fairly solid (peripheral vascular disease, chronic wound healing). It is not a cure-all, and the evidence base suffers from a shortage of large, double-blinded trials.
If you are considering MAH, the most important factors are finding a properly trained practitioner with calibrated equipment, having realistic expectations about what ozone therapy can and cannot do, and understanding that it works best as part of a broader treatment plan rather than a standalone fix. For more on ozone therapy and its various forms, including 10-pass ozone, visit our detailed guides.
